Ingredient: Insulin Glulisine
Manufacturer: Sanofi-Aventis
Brand Name: Apidra
Category: Diabetes
Apidra Solostar 100 IU 5 pens x 3 ml (1 box)
Item price: $80.00
Apidra SoloStar indications for use
Indications for use of the drug Apidra SoloStar is the treatment of diabetes in adults when insulin therapy is necessary.
Clinical Pharmacology
Hypoglycemic drug. Insulin glulisin is a recombinant analogue of human insulin, which is equivalent in effect to ordinary human insulin. The action of insulin glulisin occurs faster, and the duration of action is shorter than that of standard human insulin. The mechanism of action of insulin glulisin is the regulation of glucose metabolism.
Insulin preparations lower blood glucose levels by stimulating peripheral glucose consumption, especially skeletal muscle and adipose tissue, as well as by suppressing glucose production by the liver. Insulin suppresses lipolysis in adipocytes, inhibits proteolysis and stimulates protein synthesis.
With sc administration, the action of insulin glulisin begins much earlier and lasts shorter compared to human insulin preparations: its hypoglycemic activity begins in 10-20 minutes. The hypoglycemic effects of insulin glulisin and human insulin are equivalent when given intravenously. One unit of insulin glulisin has the same hypoglycemic effect as one unit of human insulin.
Release form and composition
Solution for subcutaneous administration.
1 ml contains insulin glulisin 100 IU (3.49 mg); excipients: metacresol (m-cresol), trometamol, sodium chloride, polysorbate 20, sodium hydroxide, hydrochloric acid, water d / and.
Special instructions
Transfer of the patient to a new type of insulin or insulin from another manufacturer should be carried out under strict medical supervision, as dose changes may be required due to changes in insulin concentration, brand (manufacturer), type of insulin (soluble, insulin-isophan, etc.), type of insulin (animal origin) and / or production method. In addition, correction of concomitant oral hypoglycemic therapy may be required.
Using inadequate doses of insulin or stopping treatment, especially in patients with type 1 diabetes, can lead to hyperglycemia and diabetic ketoacidosis, conditions that are potentially life-threatening.
Interaction
No pharmacokinetic interaction studies have been conducted. Based on existing empirical knowledge regarding other similar drugs, the appearance of a clinically significant pharmacokinetic interaction is unlikely. Some substances may affect glucose metabolism, which may require dose adjustment of insulin glulisin and especially careful monitoring of treatment.
- apidra solostar 100 units/ml
- apidra solostar 100 iu/ml
- apidra solostar 100 iu/ml 3ml
- apidra solostar 100ui/ml
- apidra solostar u-100 insulin
Substances that can increase the hypoglycemic effect of insulin and increase the predisposition to hypoglycemia include: oral hypoglycemic agents, angiotensin converting enzyme inhibitors, disopyramides, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, propoxyphenic sulfamic amidicides, salicamicides. Substances that can reduce the hypoglycemic effect of insulin include: corticosteroids, danazole, diazoxide, diuretics, isoniazid, phenothiazine derivatives, somatropin, sympathomimetics (e.g. epinephrine (adrenaline), salbutamol, terbutaline), thyroid hormones, estrogen, progestins, e.g. progestins contraceptives), protease inhibitors and antipsychotic drugs (e.g. olanzapine and clozapine).
Comments
Post a Comment